The resistance might have occurred because the chemotherapy used in the treatment of myeloma stimulated the synthesis and shedding of syndecan-1, which led to the accumulation of high levels of syndecan-1, thus enhancing relapse and promoting tumor progression. Here, SDC1 is linked to neoplasm.